267 related articles for article (PubMed ID: 37287049)
21. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
Lu JC; Zhang PF; Huang XY; Guo XJ; Gao C; Zeng HY; Zheng YM; Wang SW; Cai JB; Sun QM; Shi YH; Zhou J; Ke AW; Shi GM; Fan J
J Hematol Oncol; 2021 Nov; 14(1):200. PubMed ID: 34838121
[TBL] [Abstract][Full Text] [Related]
22. Reversal of the CD8
Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C
Front Immunol; 2021; 12():687296. PubMed ID: 34177939
[TBL] [Abstract][Full Text] [Related]
23. Targeting adenosine for cancer immunotherapy.
Leone RD; Emens LA
J Immunother Cancer; 2018 Jun; 6(1):57. PubMed ID: 29914571
[TBL] [Abstract][Full Text] [Related]
24. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X; Xie L
J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
[TBL] [Abstract][Full Text] [Related]
25. CD73 on T Cells Orchestrates Cardiac Wound Healing After Myocardial Infarction by Purinergic Metabolic Reprogramming.
Borg N; Alter C; Görldt N; Jacoby C; Ding Z; Steckel B; Quast C; Bönner F; Friebe D; Temme S; Flögel U; Schrader J
Circulation; 2017 Jul; 136(3):297-313. PubMed ID: 28432149
[TBL] [Abstract][Full Text] [Related]
26. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G
Front Immunol; 2019; 10():925. PubMed ID: 31244820
[TBL] [Abstract][Full Text] [Related]
27. Adenosine and adenosine receptors in colorectal cancer.
Hajizadeh F; Masjedi A; Heydarzedeh Asl S; Karoon Kiani F; Peydaveisi M; Ghalamfarsa G; Jadidi-Niaragh F; Sevbitov A
Int Immunopharmacol; 2020 Oct; 87():106853. PubMed ID: 32755765
[TBL] [Abstract][Full Text] [Related]
28. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
[TBL] [Abstract][Full Text] [Related]
29. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.
Montalbán Del Barrio I; Penski C; Schlahsa L; Stein RG; Diessner J; Wöckel A; Dietl J; Lutz MB; Mittelbronn M; Wischhusen J; Häusler SFM
J Immunother Cancer; 2016; 4():49. PubMed ID: 27532024
[TBL] [Abstract][Full Text] [Related]
30. Unlocking antitumor immunity with adenosine receptor blockers.
Remley VA; Linden J; Bauer TW; Dimastromatteo J
Cancer Drug Resist; 2023; 6(4):748-767. PubMed ID: 38263981
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
32. CD39
Ahlmanner F; Sundström P; Akeus P; Eklöf J; Börjesson L; Gustavsson B; Lindskog EB; Raghavan S; Quiding-Järbrink M
Oncotarget; 2018 Dec; 9(97):36993-37007. PubMed ID: 30651930
[TBL] [Abstract][Full Text] [Related]
33. SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties.
Warren MC; Matissek S; Rausch M; Panduro M; Hall RJ; Dulak A; Brennan D; Das Yekkirala S; Koseoglu S; Masia R; Yang Y; Reddy N; Prenovitz R; Strand J; Zaidi T; Devereaux E; Foissac CJ; Stagg J; Lee BH; Holland P; Palombella VJ; Lake AC
Immunohorizons; 2023 May; 7(5):366-379. PubMed ID: 37219538
[TBL] [Abstract][Full Text] [Related]
34. The role of the CD39-CD73-adenosine pathway in liver disease.
Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
[TBL] [Abstract][Full Text] [Related]
35. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
Steingold JM; Hatfield SM
Front Immunol; 2020; 11():570041. PubMed ID: 33117358
[TBL] [Abstract][Full Text] [Related]
36. Targeting the adenosine pathway for cancer immunotherapy.
Hammami A; Allard D; Allard B; Stagg J
Semin Immunol; 2019 Apr; 42():101304. PubMed ID: 31604539
[TBL] [Abstract][Full Text] [Related]
37. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches.
Thompson EA; Powell JD
Annu Rev Med; 2021 Jan; 72():331-348. PubMed ID: 32903139
[TBL] [Abstract][Full Text] [Related]
39. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H
PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099
[TBL] [Abstract][Full Text] [Related]
40. CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker.
Li C; Zhang L; Jin Q; Jiang H; Wu C
Biomark Med; 2023 Jun; 17(12):563-576. PubMed ID: 37713234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
